Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410761 · ClinicalTrials.gov registry record · Phase 3
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
NCT00410761 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 331 participants.
The verdict
NCT00410761, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
Interventions
- DRUG ZD6474 (Vandetanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2006-11-23 |
| Est. Completion | 2024-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410761
The ClinicalTrials.gov registry entry for NCT00410761 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZD6474 (Vandetanib) is the first listed.
NCT00410761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410761 about?
NCT00410761 is a clinical study titled "An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer". The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
What is the current status of trial NCT00410761?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2006-11-23. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT00410761?
The interventions under investigation include: ZD6474 (Vandetanib) (DRUG).
Who is sponsoring clinical trial NCT00410761?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.